Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe least painful injection sites for Mounjaro are the abdomen, outer thigh, and upper arm, with the abdomen most consistently rated comfortable by people using tirzepatide in clinical practice. Mounjaro's licensed prescribing information lists all three sites as suitable for subcutaneous injection, and rotating between them helps prevent soreness building up in any single spot. That rotation principle comes straight from NHS guidance on tirzepatide and the medicine's own Patient Information Leaflet. Mounjaro is a prescription-only medicine; a GPhC-registered prescriber decides whether it is clinically suitable for you before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro's Summary of Product Characteristics, available on the Electronic Medicines Compendium, specifies three valid subcutaneous sites: the abdomen (at least 5 cm away from the navel), the outer thigh, and the upper arm. Each delivers the medicine into subcutaneous fat, which has fewer pain receptors than muscle and good vascular supply for absorption.
Clinical practice data consistently point to the lower abdomen as the site most people find least uncomfortable. There is more subcutaneous fat there for most adults, the area is easy to pinch and stabilise, and the angle of the KwikPen sits naturally against the skin without awkward wrist rotation. The outer thigh is a close second, especially useful for people who prefer to self-inject sitting down. The upper arm is perfectly valid but genuinely harder to manage solo: stabilising a pen against the back of your arm while keeping the muscle relaxed is tricky, and the subcutaneous layer can be thin for leaner individuals, which increases the chance of catching muscle fibres.
If you are moving between sites week to week, the abdomen and thigh make the most practical pair for unassisted self-injection. Save the upper arm for occasions when someone else is administering the dose, or when you have found a reliable technique that works for you. If you are weighing up the options, our guide on where is the best place to inject Mounjaro walks through each site in practical detail, and our detailed guide on the best place to inject Mounjaro covers site selection in more depth if you want to read further.
Cold medication stings. This is one of the most consistently reported causes of injection discomfort across GLP-1 medicines, and it is entirely avoidable. Mounjaro's KwikPen is stored in the fridge (2–8°C) between doses. Taking it straight from the fridge door and injecting immediately means the solution enters the tissue several degrees below body temperature, triggering a noticeable burning sensation that can last 30–60 seconds.
Letting the pen sit on the counter for 20–30 minutes before injecting allows the solution to reach closer to room temperature. The difference is real and reported by a large proportion of people who switch to this habit. Keep the pen out of direct sunlight and away from heat sources while it is warming. Do not shake it, and do not try to speed the process with warm water or a microwave. The manufacturer's storage guidance in the leaflet is the reference for the exact conditions permitted.
Once you have chosen your site and the pen is at room temperature, a few other technique points compound the benefit: clean the skin with an alcohol swab and let it dry fully before injecting (wet alcohol on skin also adds sting), gently pinch a fold of skin and hold the pen steady for the full ten seconds after the click before removing it. Tensing the muscle underneath is the other common culprit for soreness that follows injection day, worth consciously relaxing the thigh or arm before pressing the button.
A common pattern: the first few weeks are fine, then a particular spot starts to feel tender, lumpy or bruised. This is usually lipohypertrophy developing, small nodules of thickened subcutaneous tissue that form when the same 2 cm radius gets repeated needle trauma. Injecting into a lipohypertrophic patch also impairs absorption, meaning the medicine may not reach full effectiveness from that site.
Systematic rotation prevents it. Map out a mental grid across your abdomen or thigh: each injection moves at least 2–3 cm from the previous one. When you have worked across the whole area, start again. Keeping a brief note on your phone, or marking your injection day on the calendar alongside a rough grid reference, is more reliable than memory. People who find this habit useful often tie it to their weekly routine, some pair the note with the reminder they set for their injection day itself.
If you notice a lump that is not resolving, avoid that area and mention it at your next prescriber review. Concerns about your injection sites are exactly the kind of thing the aftercare team at a regulated service like ours is there to help with. You can also read about whether Mounjaro injections are painful generally for a broader look at what is typical and what warrants a closer look.
Some people experience redness, swelling or prolonged itching at the injection site. Mild, short-lived reactions are common and listed in the Patient Information Leaflet as injection-site reactions. They usually settle within a day or two. Rotating sites and ensuring the skin is clean and dry before injecting reduces their frequency.
Persistent redness, significant swelling, warmth that spreads beyond the injection site, or any sign of infection should be assessed by a clinician promptly, these are not just technique problems. Similarly, generalised allergic symptoms (facial swelling, throat tightening, rash spreading away from the site) need urgent medical attention. You can report unexpected reactions through the MHRA's Yellow Card scheme, which collects safety data on medicines including tirzepatide and helps regulators identify patterns across the population.
If you are getting consistent injection pain despite adjusting your site and technique, raise it at your next clinical review rather than persevering in silence. Prescribers can sometimes suggest adjustments, and occasionally pain at the site points to a needle-change habit worth reviewing. Changing the needle for each dose matters more than many people realise; a used needle is fractionally blunter and more likely to drag through the skin. More on Mounjaro injection practice is available if you want to read about needle-change frequency and technique in detail.
For those still weighing up whether tirzepatide is right for them, our Mounjaro overview covers how the medicine works, who it is licensed for, and what the clinical trial results showed, a useful starting point before thinking about the practicalities of weekly injections. Treatment pricing is on the Mounjaro cost page if that is where your questions are heading next.
Ready to find out whether Mounjaro is clinically suitable for you? Check your eligibility with a free consultation, reviewed the same day by one of our GPhC-registered prescribers, with no waiting list.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.